The compound at the heart of the work is taraxasterol, a pentacyclic triterpenoid extracted from the roots of the common dandelion, Taraxacum officinale. Taraxasterol has long attracted attention for its antioxidant, anti-inflammatory, and anti-apoptotic activities, and it features in several traditional liver-protective herbal formulations. Yet its clinical promise has been strangled by biopharmaceutical realities. The molecule barely dissolves in water, crosses the intestinal wall poorly, and is actively pumped back out of gut cells by P-glycoprotein, a well-known efflux transporter. The research team, led by Zimin Cai and colleagues at Guizhou Medical University, quantified these barriers precisely. In a Caco-2 cell monolayer model mimicking the intestinal epithelium, taraxasterol showed an apparent permeability coefficient of just 0.79 × 10⁻⁶ cm/s. Adding verapamil, a P-glycoprotein inhibitor, boosted its transport roughly 3.6-fold, confirming the efflux problem. In mice, the absolute oral bioavailability of free taraxasterol measured a dismal 6.4 percent.

To attack the solubility problem first, the team turned to nanocrystal technology, which shrinks drug particles to the nanometer scale to dramatically increase surface area and dissolution rate. They prepared taraxasterol nanocrystals using three candidate stabilizers: poloxamer 407, polyvinyl alcohol, and D-α-tocopherol polyethylene glycol succinate, better known as TPGS, an FDA-approved excipient with a hidden talent. TPGS inhibits P-glycoprotein, meaning it can simultaneously stabilize the nanocrystals and silence the efflux pump that would otherwise expel the drug from intestinal cells. At an optimized stabilizer concentration of 1 percent, the TPGS-stabilized nanocrystals measured roughly 148 nanometers in diameter with a narrow size distribution. They also reduced the lattice energy of the crystalline drug, and dissolution testing showed the payoff: while free taraxasterol achieved only 25.6 percent cumulative dissolution over 24 hours, the TPGS nanocrystals reached 88.4 percent, a 3.45-fold improvement. In transport studies, the TPGS formulation raised apparent permeability 2.6-fold and significantly increased uptake by hepatocytes, the liver cells that ultimately need the drug.

But dissolution alone was not enough, and the researchers knew it. Orally delivered nanocrystals face a gauntlet of further obstacles: the acidic, enzyme-rich stomach, the rapidly renewing mucus layer, and the tight junctions that seal the gaps between epithelial cells. Their answer was a mucoadhesive micropatch built from a polyelectrolyte complex of chitosan and carbopol, two oppositely charged polymers that bind electrostatically. The bilayer patch uses ethyl cellulose as a waterproof backing and the chitosan-carbopol complex as the adhesive layer. When hydrated in the intestine, the patch swells into a gel-like network that physically confines the nanocrystals, creating a diffusion barrier that moderates release and prevents aggregation. As the matrix gradually erodes, intact nanocrystals are progressively freed. Infrared spectroscopy and thermal analysis confirmed the electrostatic complex formation, and scanning electron microscopy showed that nanocrystal-loaded patches had smooth, homogeneous surfaces, while patches loaded with free drug displayed ugly crystalline deposits. Over 24 hours, the nanocrystal patches released 80.75 percent of their payload, compared with a mere 23.58 percent for free-drug patches.

The absorption experiments revealed an elegant dual mechanism. In permeation studies across excised porcine intestinal mucosa, the nanocrystal-loaded polyelectrolyte patches achieved the highest cumulative transport of any formulation. In Caco-2 models, including a mucus-containing co-culture that better mimics the real intestinal environment, the patches boosted permeability through two complementary routes. Transcellular uptake rose thanks to nanocrystal internalization and TPGS-mediated efflux suppression. Paracellular transport increased because the chitosan component transiently opened the tight junctions, a process the team verified by measuring transepithelial electrical resistance, which dropped in a time-dependent manner and recovered after patch removal. Immunofluorescence staining showed downregulation of the tight junction proteins ZO-1 and claudin-4, with chitosan identified as the primary contributor to this reversible modulation. Crucially, the opening was temporary, and cell viability remained above 85 percent across all tested concentrations, indicating the barrier disruption does not come at the cost of tissue damage.

To make sure the patches actually reach the intestine rather than sticking in the stomach, the researchers packaged twenty micropatches into a single enteric-coated capsule. In simulated gastric fluid at pH 1.2, the capsules stayed intact for at least two hours; transferred to intestinal conditions at pH 6.8, they disintegrated within fifteen minutes. A magnesium stearate coating prevented the released patches from clumping together. In vivo fluorescence imaging in mice told a striking story: while free dye and plain nanocrystals were swept through the gastrointestinal tract within hours, the micropatch capsules produced strong, persistent signals in the small intestine for up to 12 hours after administration. The patches were seen adhering to the luminal side of the intestinal mucosa, visibly swollen, forming a localized drug depot that maintains a high concentration gradient driving absorption.

The pharmacokinetic consequences were dramatic. Compared with free taraxasterol, the full capsule system produced a 3.1-fold increase in total drug exposure and a 5.8-fold rise in peak plasma concentration, along with a prolonged half-life and reduced clearance. Even more importantly for a liver disease, tissue distribution analysis showed the highest and most sustained drug levels in the liver itself, with hepatic enrichment persisting over 12 hours. This liver-targeting profile means therapeutic concentrations actually reach the site of injury, rather than diffusing uselessly into other organs.

With delivery solved, the team put the platform to the test in two mouse models of liver injury. In the intrinsic model, mice received acetaminophen; in the idiosyncratic model, they received the isoniazid-rifampicin combination. Treatment with the nanocrystal micropatch capsules outperformed both free taraxasterol and plain nanocrystals, and matched or exceeded silymarin, a clinically established hepatoprotective drug used as the positive control. Serum markers of liver damage, including ALT, AST, LDH, alkaline phosphatase, total bile acids, and total bilirubin, all fell significantly, and histological examination showed restored hepatic architecture. Blank capsules without the drug showed no protective effect, confirming the benefit came from taraxasterol itself, not the carrier. The formulation also cut reactive oxygen species and malondialdehyde, restored glutathione and superoxide dismutase, suppressed the inflammatory cytokines IL-1β, IL-6, and TNF-α, and reduced apoptotic cell death, with no detectable toxicity in blood counts or major organs.

To explain these effects mechanistically, the researchers employed network pharmacology, cross-referencing predicted taraxasterol targets against genes linked to both forms of drug-induced liver injury. The analysis identified 80 shared targets concentrated in three pathological axes: oxidative stress, inflammation, and apoptosis. Western blot validation in injured mouse livers confirmed the prediction. The formulation most potently activated the Nrf2/HO-1 antioxidant defense pathway, suppressed stress-activated JNK phosphorylation, and dampened the Bax/Bcl-2 ratio and caspase-3 activation that drive mitochondrial apoptosis. In essence, the delivery platform amplifies the compound’s intrinsic multi-target pharmacology simply by getting enough of it to the liver.

The authors are candid about the work’s limitations: the studies were prophylactic rather than therapeutic, long-term toxicity remains untested, and manufacturing scalability has yet to be proven. Still, the significance of the platform extends well beyond one dandelion molecule. By integrating nanocrystallization, a functional stabilizer that blocks efflux, mucoadhesive polyelectrolyte patches that transiently open tight junctions, and enteric coating for site-specific release, the team has assembled a generalizable blueprint for rescuing poorly soluble, poorly permeable natural products from formulation purgatory. For the many herbal compounds with intriguing pharmacology but hopeless bioavailability, that blueprint could be the difference between laboratory curiosity and real medicine.

Subject of Research: A nanocrystal-mucoadhesive micropatch oral delivery platform enhancing taraxasterol bioavailability for protection against drug-induced liver injury

Article Title: Boosting oral bioavailability of taraxasterol via a nanocrystal-mucoadhesive micropatch platform for potent multi-mechanistic protection against drug-induced liver injury

Article References: Cai, Z., Zhao, H., Wei, M., Cheng, Z., He, H., Xu, J., Xu, S., Huang, J., Xiao, T., Peng, J., Sun, R., Du, Q., & Chen, Y. (2026). Boosting oral bioavailability of taraxasterol via a nanocrystal-mucoadhesive micropatch platform for potent multi-mechanistic protection against drug-induced liver injury. Materials Today Bio, 41, Article 103694. https://doi.org/10.1016/j.mtbio.2026.103694

Image Credits: AI Generated

DOI: 10.1016/j.mtbio.2026.103694

Keywords: taraxasterol, drug-induced liver injury, nanocrystals, oral drug delivery, mucoadhesive micropatch, TPGS, chitosan, carbopol, Nrf2/HO-1 pathway, acetaminophen, bioavailability, hepatoprotection